Medexus Pharmaceuticals Inc (TSXV:MDP) (OTCQX:MEDXF) (FRA:P731) CEO Ken d’Entremont tells Proactive it has initiated the Canadian commercial launch of Gleolan, a powder-based optical imaging agent taken orally by patients to help surgeons identify brain and spinal cord tumors called gliomas.
d’Entremont says the agent had previously only been distributed under the Health Canada Special Access Program.
There are currently no other optical imaging agents approved in Canada for the purpose of visualization of malignant tissue during glioma surgery.